Relative Bioavailability Study of GSK1265744 Formulations

NCT01648257 | Completed Phase 1

• 1 other identifier: 116585
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 1

Brief Summary

This is a single-center, randomized, open-label, balanced, 3 way crossover study (3 periods) in healthy adult subjects. During each period, subjects will receive a single dose of GSK1265744 oral formulation in the fasted state and serial PK sampling for up to 168 hours (8 days) and safety assessments will be performed. Each period will be separated by a washout period of at least 14 days and a follow-up visit will occur 10 to 14 days after the last dose of study drug.

Conditions

Infections, Human Immunodeficiency Virus and Hepatitis

Keywords

healthy subjects; relative bioavailability; HIV; GSK1265744

Outcome Measures

Primary Outcomes (1)

• Composite of PK parameters following single oral dose administration of GSK1265744

  Plasma GSK1265744 PK parameters: area under the concentration-time curve (AUC) from time zero (pre-dose) extrapolated to infinite time AUC(0-infinity); AUC from time zero to time t, AUC(0-t), and maximum observed concentration, Cmax.

  For 168 hours post dose (36 days)

Secondary Outcomes (6)

• Composite of PK parameters following single oral dose administration of GSK1265744

  For 168 hours post each dose of GSK1265744 (36 days)

• Safety and tolerability as assessed by the collection of adverse events

  50 days

• Safety and tolerability as assessed by change from baseline in clinical laboratory tests

  50 days

• Safety and tolerability as assessed by change from baseline in electrocardiogram (ECG)

  50 days

• Safety and tolerability as assessed by change from baseline in vital signs

  50 days

Study Arms (3)

GSK1265744 Na Salt Tablets

EXPERIMENTAL

Subjects will receive single dose of GSK1265744 sodium salt (30 mg) tablet on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 milliliter (mL) of water.

Drug: GSK1265744 Na Salt Tablets

GSK1265744 Free Acid Nanomilled Capsules

EXPERIMENTAL

Subjects will receive single dose of GSK1265744 free acid nanomilled (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.

Drug: GSK1265744 Free Acid Nanomilled Capsules

GSK1265744 Free Acid Micronized Capsules

EXPERIMENTAL

Subjects will receive single dose of GSK1265744 free acid micronized (30 mg) capsule on Day 1 of the respective period per randomized sequence, orally in fasted condition, with 240 mL of water.

Drug: GSK1265744 Free Acid Micronized Capsules

Interventions

GSK1265744 Na Salt Tablets DRUG

Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.

GSK1265744 Na Salt Tablets

GSK1265744 Free Acid Nanomilled Capsules DRUG

Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.

GSK1265744 Free Acid Nanomilled Capsules

GSK1265744 Free Acid Micronized Capsules DRUG

Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.

GSK1265744 Free Acid Micronized Capsules

Eligibility Criteria

• Age: 18 Years - 64 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin =\< 1.5x upper limit of normal (ULN) (isolated bilirubin \>1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
• Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinically significant abnormality or laboratory parameter outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
• Male or female between 18 and 64 years of age inclusive, at the time of signing the informed consent.
• A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation, bilateral salpingo-oophorectomy or hysterectomy; postmenopausal defined in the protocol; or child-bearing potential and agrees to use one of the contraception methods listed in the protocol.
• Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods. This criterion must be followed from the time of the first dose of study medication until 14 days after the last dose of study medication.
• Body weight \>= 50 kilogram (kg) for men and \>= 45 kg for women and body mass index (BMI) within the range 18.5 to 31.0 kg/ (meters squared) m\^2 (inclusive).

You may not qualify if:

• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
• Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
• A positive pre-study drug/alcohol screen.
• A positive test for human immunodeficiency virus (HIV) antibody.
• History of regular alcohol consumption within 6 months of the study.
• The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
• Exposure to more than four new investigational chemical entities within 12 months prior to the first dosing day.
• Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
• History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
• Pregnant females as determined by positive urine human chorionic gonadotropin (hCG) test at screening or prior to dosing.
• Lactating females.
• Unwillingness or inability to follow the procedures outlined in the protocol.
• Subject is mentally or legally incapacitated.
• History of sensitivity to heparin or heparin-induced thrombocytopenia.

Sponsors & Collaborators

• ViiV Healthcare: lead

Study Sites (1)

GSK Investigational Site

Overland Park, Kansas, 66211, United States

Location

MeSH Terms

Conditions

Infections; Acquired Immunodeficiency Syndrome; Hepatitis

Condition Hierarchy (Ancestors)

HIV Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; RNA Virus Infections; Virus Diseases; Slow Virus Diseases; Genital Diseases; Urogenital Diseases; Immunologic Deficiency Syndromes; Immune System Diseases; Liver Diseases; Digestive System Diseases

Study Officials

• GSK Clinical Trials

  ViiV Healthcare

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 19, 2012
• First Posted: July 24, 2012
• Study Start: August 1, 2012
• Primary Completion: November 1, 2012
• Study Completion: November 1, 2012
• Last Updated: August 12, 2016

Record last verified: 2016-08

Locations

US (1)